Your browser doesn't support javascript.
loading
Follow-up of human adenovirus viral load in pediatric hematopoietic stem cell transplant recipients.
Peker, Bilal Olcay; Tüysüz Kintrup, Gülen; Saglik, Imran; Can Sarinoglu, Rabia; Güler, Elif; Mutlu, Derya; Küpesiz, Osman Alphan; Çolak, Dilek.
Afiliación
  • Peker BO; Department of Medical Microbiology, Izmir Katip Çelebi University Atatürk Training and Research Hospital, Izmir, Turkey.
  • Tüysüz Kintrup G; Department of Pediatric Hematology and Oncology, Akdeniz University Medical Faculty, Antalya, Turkey.
  • Saglik I; Department of Medical Microbiology, Uludag University Medical Faculty, Bursa, Turkey.
  • Can Sarinoglu R; Department of Medical Microbiology, Marmara University Pendik Research and Training Hospital, Istanbul, Turkey.
  • Güler E; Department of Pediatric Hematology and Oncology, Akdeniz University Medical Faculty, Antalya, Turkey.
  • Mutlu D; Department of Medical Microbiology, Division of Medical Virology, Akdeniz University Medical Faculty, Antalya, Turkey.
  • Küpesiz OA; Department of Pediatric Hematology and Oncology, Akdeniz University Medical Faculty, Antalya, Turkey.
  • Çolak D; Department of Medical Microbiology, Division of Medical Virology, Akdeniz University Medical Faculty, Antalya, Turkey.
Clin Transplant ; 35(3): e14209, 2021 03.
Article en En | MEDLINE | ID: mdl-33368539
BACKGROUND: The spectrum of human adenovirus (HAdV)-related disease is broad, and the virus acts on many organs and systems in hematopoietic stem cell transplantation (HSCT) recipients. We aimed to evaluate the effect of HAdV-DNA positivity with clinical and laboratory findings 4 months after HSCT. METHODS AND RESULTS: We retrospectively investigated HAdV-DNA in 153 HSCT recipients (≤18 years) by quantitative real-time polymerase chain reaction (RealStar; Altona Diagnostics). The results of samples from January 2014 to December 2017 are included. HAdV-DNA was positive for at least one sample type in 50 (32.67%) patients. HAdV-DNA positivity rate was 8.92% (N: 145/1625), 40.25% (N: 64/159), and 25% (N: 2/8) for plasma, stool, and urine samples, respectively. HAdV-DNA was positive in the plasma of 38 (24.83%) patients at a median 16 (range: 1-58 days) days after HSCT. The mortality rate was 23.68% and 6.95% in plasma HAdV-positive and HAdV-negative patients (p = .014). Moreover, HAdV-DNA positivity had an impact on overall survival for allogeneic-HSCT (p = .013), with the cumulative effect including graft-versus-host disease state in multivariate analysis (p = .014). CONCLUSIONS: Plasma HAdV-DNA positivity is a potential influencer that decreases survival in the early post-transplant period. Due to the high mortality rates, close monitoring is required of HAdV infections after HSCT with sensitive methods, especially at the early stage.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenovirus Humanos / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Child / Humans Idioma: En Revista: Clin Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Dinamarca
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Adenovirus Humanos / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Child / Humans Idioma: En Revista: Clin Transplant Asunto de la revista: TRANSPLANTE Año: 2021 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Dinamarca